Geneos Wealth Management
CAPR icon

Geneos Wealth Management’s Capricor Therapeutics CAPR Stock Holding History

Geneos Wealth Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.84K Hold
300
– – ﹤0.01% 2817
2026
Q2 		$7.22K Hold
300
– – ﹤0.01% 2096
2026
Q1 		$9.12K Buy
+300
New +$7.99K ﹤0.01% 2010

Other funds holding CAPR

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
DG Capital Management
DG Capital Management New York $451M AUM 20.71% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
HBK Sorce Advisory
HBK Sorce Advisory Erie, Pennsylvania $5.18B AUM 12.38% 1-Year Est. Return

Geneos Wealth Management's CAPR Position: Q3 2026 in Review

Geneos Wealth Management held its Capricor Therapeutics (CAPR) position steady in Q3 2026 at 300 shares worth $2.84K. The position accounts for ﹤0.01% of the portfolio, ranked #2817.

Geneos Wealth Management first reported a position in CAPR in Q1 2026 and has held it in 3 quarters since. The position peaked at $9.12K in Q1 2026. 81 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Geneos Wealth Management held 300 shares of Capricor Therapeutics worth $2.84K as of Q3 2026.
  • Geneos Wealth Management left its Capricor Therapeutics share count unchanged in Q3 2026.
  • Capricor Therapeutics made up ﹤0.01% of Geneos Wealth Management's portfolio in Q3 2026, its #2817 holding.
  • Geneos Wealth Management first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Geneos Wealth Management's Capricor Therapeutics position peaked at $9.12K in Q1 2026.
  • 81 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Geneos Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.